A Phase III Open-Label, Multicenter, Randomized, Active-Controlled Study to Compare the Efficacy, Pharmacokinetics, Safety, and Tolerability of P1101 vs Anagrelide as Second-Line Therapy for Essential Thrombocythemia.

Brief Summary

Type:
Hematologic - Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04285086

Study #:
STUDY00146331

Start Date:
Jan 19, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04285086

View Complete Trial Details & Eligibility at ClinicalTrials.gov